It will be ideal to compare SLCO2B1 expression level between primary tumor with and without metastasis because EMT is a well-known mechanism in metastatic disease and cancer progression, and validate SLCO2B1 expression level and recurrence using another cohort. This evidence concerns the gene SLCO2B1 and metastatic neoplasm.